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Abstract 
We once proposed that cell-type-associated chromatin configurations deter-
mine cell types and that cancer cell type is determined by cancer-associated 
chromatin configuration (CACC). In this paper, we hypothesize that flexible 
cell-type-associated chromatin configuration is associated with cell potency 
and has an advantage over inflexible one in regulating genome related activi-
ties, such as DNA replication, DNA transcription, DNA repair, and DNA 
mutagenesis. The reason why cancer is so difficult to treat is because CACC is 
flexible, which enables cancer cells not only to produce heterogeneous sub-
clones through limited cell differentiation, but also to maximally and effi-
ciently use genome related resources to survive environmental changes. 
Therefore, to beat cancer, more efforts should be made to restrict the flexibil-
ity of CACC or to change CACC so that cancer cells can be turned back to 
normal or become less malignant. 
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1. Introduction 
Currently, it is well accepted that heterogeneity in cancers is the major reason 
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why most cancers are so difficult to cure [1] [2]. However, the mechanism by 
which heterogeneous cancer cells or subclones in cancer cell populations are 
produced is not fully elucidated. The mainstream viewpoints blame genome in-
stability for being the cause of cancer heterogeneity [3] [4], but we think that 
genome instability is only a superficial description about cancer genome, not a 
mechanism of how cancer heterogeneity is generated. Furthermore, we don’t 
think that heterogeneity is the fundamental obstacle to beating cancer. 
More than 30 years ago, we published a hypothesis that abnormal chromatin 
configuration might be associated with oncogenesis [5] [6], which has been strongly 
supported by research evidence [7] [8]. Recently, we published another hypothe-
sis that a group of unknown rivet proteins might be involved in the formation of 
cell-type-associated chromatin configuration which determines a cell type and 
that cancer is the cell type that is determined by cancer-associated chromatin 
configuration (CACC) [9]. Based on this hypothesis, the number of rivet protein 
fastened-sites in the three-dimensional (3D) genome architecture determines the 
flexibility of cell-type-associated chromatin configurations. Compared to normal 
cell’s cell-type-associated chromatin configuration, CACC is more flexible, which 
might be the fundamental reason why cancer is so difficult to cure. Detailed de-
scription about our viewpoints is presented in this paper. 
2. Flexible CACC Might Be Associated with Cancer Cell  
Potency and Cancer Heterogeneity  
Based on our recently published hypothesis [9], the flexibility of cell-type-associated 
chromatin configuration is proportional to cell potency because more flexible 
chromatin configurations might regulate more gene expressions, and inversely 
proportional to the number of rivet protein fastened-sites in the 3D genome ar-
chitecture because more rivet protein fastened-sites in the 3D genome architec-
ture mean more restrictions on the flexibility of cell-type-associated chromatin 
configuration, for instance, highly differentiated cells might have the largest 
number of rivet protein fastened-sites in their genome architectures and thus 
have the least flexibility in their chromatin configurations and the least cell potency, 
whereas stem cells might have the least number of rivet protein fastened-sites in 
their genome architectures and thus have the most flexibility in their chromatin 
configurations and the greatest cell potency. The number of rivet protein fas-
tened-sites in cancer genome architecture is much less than those in normal so-
matic cell’s genome architecture but a bit more than those in somatic stem cell’s 
genome architecture, therefore, cancer cell potency is between stem cell and so-
matic cell, which enables cancer cell to undergo limited differentiation.  
Apparently, cell differentiation is also the process during which cell potency is 
gradually restricted by increasing rivet protein fastened-sites in the 3D genome 
architectures of cells that undergo differentiation, whereas cell dedifferentiation 
is the process during which cell potency is gradually increased by reducing the 
number of rivet protein fastened-sites in the 3D genome architectures of cells 
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that undergo dedifferentiation. Under long-term exposure to carcinogens, both 
somatic cells and somatic stem cells can become cancer cells, but the mechan-
isms by which they become cancerous might be a bit different, for instance, a can-
cer cell arrived from a somatic cell might be caused by abnormal dedifferentiation 
which involved in the reduction of the number of rivet protein fastened-sites, 
whereas a cancer cell arrived from somatic stem cell might be caused by abnormal 
differentiation which involved in the addition of the number of rivet protein fas-
tened-sites. However, no matter whether a cancer cell comes from a somatic cell or 
somatic stem cell, its cell-type-associated chromatin configuration must be CACC. 
We think that CACC in all cancers might have the same or similar fundamental 
structure because all cancers have the same hallmarks, such as limitless replicative 
potential, evading apoptosis, tissue invasion and metastasis etc. [10]. 
Cell-type-specific rivet protein fastened-site patterns in the 3D genome archi-
tectures determine cell-type-associated chromatin configurations which determine 
cell types. In our human body there are about 200 cell types, which are required 
in the maintenance of a healthy human body and thus are purposely produced 
during evolution from unicellular organisms to multicellular organisms. Cancer 
cell type is not purposely produced in human body because it kills its host. The 
reason why human body can produce cancer cell type is because CACC that de-
termines cancer cell type is formed by cancer-cell-type-specific rivet protein fas-
tened-site pattern in the genome architecture, which is accidentally selected 
from various randomly-generated rivet protein fastened-site patterns during 
long-term exposure to carcinogens. Since the formation of CACC is a rare event, 
which does not affect the survival of multicellular-organism populations during 
evolution, CACC’s blueprint is preserved in the genome of multicellular organ-
isms including our humans. 
Under certain conditions, a cell type can be converted into another and vice 
versa, which could be named as cell type transition. The underlying mechanism 
of cell type transition is cell-type-associated chromatin configuration transition 
resulting from cell-type-specific rivet protein fastened-site pattern transition [9]. 
Cell type transitions is common in multicellular organisms, for instance, em-
bryonic stem cell differentiates into different somatic cells, normal somatic cells 
or a stem cells becomes cancer cells, and differentiated cells becomes iPS cells, all of 
which belong to different cell type transitions. Slight change in cell-type-associated 
chromatin configuration might not completely change cell type but might con-
vert one cell type to its subtype or subclone, this type of cell type transition could be 
named as partial cell type transition, for example, conversion of a drug-sensitive 
cell type to drug-resistant cell type. Cancer heterogeneity might be caused by 
partial cell type transition, which is closely related to cancer cell potency. Per-
haps, when microenvironment is favorable for cancer cell growth, a cancer cell 
type will undergo cell division to produce many identical cancer cells (clone ex-
pansion), but if there are microenvironmental changes or certain differentia-
tion-inducing molecules (for example, certain drugs), the cancer cell type will 
undergo limited differentiation to produce many heterogeneous cancer cells (sub-
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clones) which further form heterogeneous cancer populations through clone ex-
pansion. The susceptibility of these subclones to chemotherapy，radiotherapy 
and immunotherapy is different, some are innately resistant to them, leading to 
cancer recurrence and others might be responsible for cancer metastasis. Ob-
viously, the limited differentiation performed by cancer cells causes partial cell 
type transitions, which perhaps is an important defensive strategy used by can-
cer cells to survive environmental changes. The following schematic diagram 
(Figure 1) summarizes our viewpoints about cancer initiation and cancer hete-
rogeneity formation. 
Taken together, at the cellular level, it seems that the reason why most cancers 
are so difficult to cure is due to cancer heterogeneity, but at the genome archi-
tecture level, the reason is due to flexible CACC which enables cancer cells to 
produce heterogeneous subclones through limited differentiation triggered by 
environmental changes.  
 
 
Figure 1. Schematic diagram of cancer initiation and cancer heterogeneity formation. 
Cell-type-associated chromatin configurations (blue) and rivet protein fastened-sites 
(red) in different cell types are shown in the diagram. 
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3. Flexible CACC Might Have an Advantage in Regulating  
Genome Related Activities 
In the recent decades, a growing number of studies have shown that chromatin 
configuration or the 3D genome architecture plays an important role in regulat-
ing genome related activities, such as DNA replication, DNA transcription, and 
DNA repair [11]. This regulation might not be one-way, the genome related ac-
tivities could also affect dynamic chromatin configuration. We once proposed 
that chromatin configuration and gene activity might mutually regulate each 
other, leading to a chain reaction-like regulation pattern during cell cycle pro-
gression [6]. Now we think that this type of regulation might also apply to cell 
differentiation and cell type transition. 
We here propose that the flexibility of cell-type-associated chromatin confi-
guration determines not only cell potency but also the efficiency of cell-type as-
sociated chromatin configuration in regulating genome related activities. 
Cell-type associated chromatin configuration sets up the framework for cell-type 
specific gene expression pattern and epigenetic modification pattern, and within 
this framework, genome related activities are regulated by dynamic genome ar-
chitecture through providing suitable spatial-structure to trigger various 
machineries (DNA replication machinery, DNA transcription machinery, and 
DNA repair machinery) to work. Obviously, this type of regulation takes time, 
and flexible cell-type-associated chromatin configuration might make this regu-
lation more efficient or timesaving. Therefore, compared to normal cells, cancer 
cell can efficiently regulate the genome related activities when they need to do so 
because CACC is flexible. Furthermore, flexible CACC enables cancer cells to 
maximally use genome related resources to survive environmental changes, for in-
stance, cancer cells can take different pathways whenever they need to bypass the 
blocked pathways caused by any anticancer drugs.  
We think that generation of DNA mutations, i.e., DNA mutagenesis, also be-
longs to genome related activity. Since generation of certain gene mutations or 
noncoding DNA mutations involves various enzymes or proteins, it is reasona-
ble to postulate that some DNA mutations are generated by DNA mutagenesis 
machinery which is also regulated by the 3D genome architecture. In another 
word, not all DNA mutations are completely randomly generated, some might 
be partially randomly generated, i.e., generation of these mutations in genes or 
noncoding DNA regions is random, but which genes or which segments of 
noncoding DNA will be mutated is not random but is guided by the dynamic 3D 
genome architecture. For example, one anticancer drug affects a protein func-
tion, which will trigger transcription of this protein’s mRNA to produce more 
such proteins, if the drug effects persist, the transcription activity will carry on, 
resulting in the formation of a transcription hotspot, which triggers the 3D ge-
nome architecture regulation, making the hotspot to move to the region in the 
3D genome architecture, which is suitable for DNA mutagenesis machinery to 
work, or to make the hotspot regional structure suitable for DNA mutagenesis 
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machinery to work and thus random mutations are generated within this protein 
gene, after natural selection some mutations will be selected so that the drug’s 
harmful effect is diminished. Therefore, this DNA mutagenesis could be named 
as the 3D genome architecture guided gene mutagenesis. No doubt, preparation 
of regional genome structure for triggering DNA mutagenesis machinery to 
work takes time, for normal cells it will take quite long time because normal 
cell’s chromatin configuration is not flexible. However, cancer cells can quickly 
complete this process because CACC is flexible. Some mutagenesis in noncoding 
DNA regions might also be regulated by the dynamic 3D genome architecture in 
the same way apart from the fact that the hotspot is not transcription hotspot, 
but any persistent blockage caused by environmental changes in the noncoding 
DNA regions. This DNA mutagenesis could be named as the 3D genome archi-
tecture guided noncoding DNA mutagenesis. 
Drug induced DNA mutations in a single gene, or few genes might contribute 
to acquired drug resistance in cancer but might not reflect the whole picture of 
how acquired drug resistance in cancer is developed. Analysis of differential 
gene expression between drug-resistant and drug-sensitive cancer cells has 
shown that hundreds of genes are either upregulated or downregulated [12], in-
dicating that drug resistance in cancers is not caused by a single or few mutated 
genes but involves wide-range gene expression changes which might be caused 
by slight change of cell-type-associated chromatin configuration. Therefore, it is 
reasonable to think that drug-resistant cancer cells might result from partial cell 
type transition and belong to subtypes of drug-sensitive cancer cells.  
The 3D genome architecture guided gene mutagenesis and natural selection 
could be considered as a type of gene regulation that regulates gene product 
quality not gene product quantity. Clearly, in evolution, gene product quality 
related gene regulation is more efficient than gene product quantity related gene 
regulation. In addition, the 3D genome architecture guided noncoding DNA 
mutagenesis might also play a role in regulation of gene expression through 
changing regional genome structure. Due to their flexible CACC, cancer cells are 
prone to using these two types of gene regulation to survive environmental 
changes, which might be the reason why in cancer cells there are so many muta-
tions in various genes and noncoding DNA regions [13] [14].  
In conclusion, flexible CACC enables cancers to undergo limited cell differen-
tiation to generate various subclones and to efficiently use genome related re-
sources to survive environmental changes, which is the fundamental reason why 
cancer is difficult to cure.  
4. Implications 
More than 30 years ago, we proposed that abnormal chromatin configuration 
might cause cancer and thus turning cancer cell’s abnormal chromatin configu-
ration to normal by any means necessary will be able to turn cancer cells back to 
normal cells [5]. This is the first viewpoint proposed to treat disease (cancer) by 
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manipulating chromatin configuration, which indicates a possibility of develop-
ing a novel class of drug, i.e., chromatin-configuration-manipulating drugs for 
treating chromatin configuration related diseases. 
In this paper we point out that flexible CACC is the fundamental reason why 
cancer is so tough to cure. Due to this reason, no matter what therapies we use 
in the treatment of cancers, cancer cells will be able to find way out of the harm-
ful situation and will return eventually. Certainly, it is impossible to kill all can-
cer cells by currently used therapies (chemotherapy, radiotherapy and immuno-
therapy) unless to kill the cancer patient first. If we cannot beat cancer by can-
cer-cell killing strategy, we should find other ways to deal with cancer, for exam-
ple, changing cancer cell behaviour through restricting the flexibility of CACC, 
perhaps, cancer differentiation therapy [15] is the therapy that restricts the flex-
ibility of CACC. We can also use less toxic agent to completely or partially 
change CACC to elicit cell type transition or partial cell type transition so that 
cancer cells might become normal or less malignant and thus can live within 
human body like benign tumours.  
As mentioned above, CACC in all cancers might have the same or similar 
fundamental structure which is determined by cancer-cell-type-specific rivet 
protein fastened-site pattern in the 3D genome architecture. The unoccupied ri-
vet protein fastened-sites are named as rivet holes which are the structures 
formed by DNA and related proteins [9]. If we know the DNA sequence in-
volved in the formation of rivet holes which are necessary for constructing the 
fundamental structure of CACC, we can remove or modify this DNA sequence 
by human embryo DNA editing so that there is no chance to form CACC in the 
3D genome architecture of the baby developed from this embryo. Possibly, in 
this way, some babies with innate resistance to cancer will be born.  
5. Conclusions  
Humans have been fighting cancers for centuries, but at present, most cancers 
remain unbeatable. Currently, mainstream viewpoints blame cancer heterogene-
ity for being a major problem in the treatment of cancers. In this paper, we pro-
pose that the fundamental reason why most cancers are incurable is because 
CACC is flexible, which enable cancer cells to efficiently use genome related re-
sources to survive environmental changes. Hence, to beat cancer, more efforts 
should be made to restrict the flexibility of CACC or to change CACC so that 
cancer cells can be turned back to normal or become less malignant.  
To support our viewpoints, identification of rivet proteins is critical. We once 
proposed that Plasmodium falciparum chloroquine resistance marker protein 
(Pfcrmp) might be one of such rivet proteins because it contains both DNA-binding 
and histone-binding domains (Q968Y0_PLAFA) [9]. We believe that Pfcrmp or 
its homologue exists in all eukaryotic cells including human cells. Therefore, 
further investigation of Pfcrmp’s role in the construction of the 3D genome ar-
chitecture might help to unveil the mystery of CACC formation. 
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